 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...3031323334353637383940...100101» |
- | Piqray (alpelisib) / Novartis
Journal: Alpelisib induced interstitial lung disease in a patient with advanced breast cancer. (Pubmed Central) - Jun 23, 2022
Drug-induced interstitial lung disease is usually a diagnosis of exclusion, difficult to identify particularly during the COVID-19 pandemic for patients with cancer. Differential diagnosis includes infectious pneumonia, radiation pneumonitis, diffuse alveolar hemorrhage, pulmonary edema, and pulmonary lymphangitic metastasis.
- || Ibrance (palbociclib) / Pfizer
Trial completion, Combination therapy: PROMETEO II: Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy (clinicaltrials.gov) - Jun 23, 2022
P1, N=22, Completed, Sponsor: SOLTI Breast Cancer Research Group
Differential diagnosis includes infectious pneumonia, radiation pneumonitis, diffuse alveolar hemorrhage, pulmonary edema, and pulmonary lymphangitic metastasis. Recruiting --> Completed
- || Clinical, Retrospective data, Review: Efficacy and Safety of Initial 5 Years of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Jun 22, 2022
In addition, the three kinds of aromatase inhibitors achieved roughly equal efficacy, but caused different types of SAEs. Systematic Review Registration: [website], identifier [registration number].
- | letrozole / Generic mfg.
Preclinical, Journal: PEGylated Protamine Letrozole Nanoparticles: A Promising Strategy to Combat Human Breast Cancer via MCF-7 Cell Lines. (Pubmed Central) - Jun 22, 2022
Moreover, the PEG-protamine letrozole NPs displayed a strong anticancer action compared to MCF-7 cells with an IC50 70 μM for letrozole and 50 μM for PEG-protamine letrozole NPs. Overall, our results indicate that letrozole PEG-protamine NPs alter the release profile of letrozole, which could be an excellent approach for overcoming letrozole resistance in human breast cancer.
- ||| Trial completion, Trial completion date, Combination therapy, Metastases: BOLERO-5: A Study of Everolimus Plus Exemestane in Chinese Postmenopausal Women With Estrogen Receptor Positive, Locally Advanced, Recurrent, or Metastatic Breast Cancer After Recurrence or Progression on Non-steroidal Aromatase Inhibitor (clinicaltrials.gov) - Jun 21, 2022
P2, N=159, Completed, Sponsor: Novartis Pharmaceuticals
Overall, our results indicate that letrozole PEG-protamine NPs alter the release profile of letrozole, which could be an excellent approach for overcoming letrozole resistance in human breast cancer. Active, not recruiting --> Completed | Trial completion date: Nov 2022 --> Apr 2022
- || letrozole / Generic mfg.
✅ Despite low response rates NACT should not be avoided; letrozole maintainance tx is suggested ☑️ Standard oncological f/u postpartum seems valid; thorough examination & F/u of the infant is needed (Twitter) - Jun 21, 2022
- ||| letrozole / Generic mfg., tamoxifen / Generic mfg.
Clinical, P2 data: @Otto_DFCI said a neoadjuvant Phase II clinical trial is now taking place looking at Tamoxifen vs. Letrozole in patients with #lobular and IDC. More to come! (Twitter) - Jun 20, 2022
- | progesterone / Generic mfg., letrozole / Generic mfg.
Journal: Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? (Pubmed Central) - Jun 20, 2022
Our results show that COSTLES for fertility preservation in breast cancer patients using GnRHa trigger reduces serum progesterone levels compared to ovarian stimulation without letrozole. These findings encourage the use of COSTLES in this context to decrease the potential deleterious effect of elevated hormonal levels on hormone-positive breast cancer.
- || Retrospective data, Review, Journal: Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis. (Pubmed Central) - Jun 19, 2022
Fertility-sparing treatment in women with endometrial cancer or hyperplasia is associated with an overall good response to therapy, good chance of achieving pregnancy and a good livebirth rate. Diagnostic follow-up with hysteroscopy was associated with a higher pregnancy rate, although this requires confirmation in adequately powered randomized trials.
- || ABSK091 / Abbisko Therap
P2a data, Clinical Trial,Phase II, Journal: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer. (Pubmed Central) - Jun 19, 2022
P2a
Eleven patients had retinal pigment epithelial detachments which was asymptomatic and reversible in all but one patient. Exploratory ribonucleic acid sequencing (RNA-Seq) analysis was done on patients' samples: 6 differentially-expressed-genes could distinguish those who benefited from the addition of AZD4547.
- | metformin / Generic mfg., atorvastatin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal, IO biomarker: Effects of metformin, letrozole and atorvastatin on inflammation and apoptosis in experimental peritoneal and ovarian endometriosis in the rat. (Pubmed Central) - Jun 15, 2022
IL-6, IL-8, and TNF-α levels were significantly lower in all medical treatment groups than in the endometriosis groups. In conclusion; Metformin, letrozole, and atorvastatin showed apoptosis induction and anti-inflammatory effects on both ovarian and peritoneal endometriosis in experimental models.
- | Tecentriq (atezolizumab) / Roche
Enrollment change, Trial withdrawal: AteBrO: Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsity (clinicaltrials.gov) - Jun 15, 2022
P1, N=0, Withdrawn, Sponsor: Universitaire Ziekenhuizen Leuven
In conclusion; Metformin, letrozole, and atorvastatin showed apoptosis induction and anti-inflammatory effects on both ovarian and peritoneal endometriosis in experimental models. N=120 --> 0 | Not yet recruiting --> Withdrawn
- | metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Retrospective data, Journal: The effect of medication on serum anti-müllerian hormone (AMH) levels in women of reproductive age: a meta-analysis. (Pubmed Central) - Jun 15, 2022
Specifically, OC, MET and CC lead to decreased AMH level, DHEA and VD lead to increased AMH level, and GnRH-a leads to dynamic variation, which is correlated with PCOS, obesity, age, and duration of medication. The impacts of these medications should be taken into consideration when AMH is used as a marker of ovarian reserve.
- | letrozole / Generic mfg.
Trial completion: Letrozole and Misoprostol for Termination of Pregnancy up to 63 Days' Gestation (clinicaltrials.gov) - Jun 15, 2022
P2, N=40, Completed, Sponsor: Gynuity Health Projects
The impacts of these medications should be taken into consideration when AMH is used as a marker of ovarian reserve. Recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
Enrollment closed: NCI-2018-01050: Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Jun 14, 2022
P1/2, N=54, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- | letrozole / Generic mfg.
Preclinical, Journal: Rhamnocitrin Attenuates Ovarian Fibrosis in Rats with Letrozole-Induced Experimental Polycystic Ovary Syndrome. (Pubmed Central) - Jun 14, 2022
Our findings suggest that Rha significantly ameliorated metabolic disturbances and ovarian fibrosis in the PCOS rats. Rha perhaps is an effective compound for preventing ovarian fibrosis in the future.
- | Ibrance (palbociclib) / Pfizer
Journal: Three-Year Progression-Free Survival of Metastatic Breast Cancer Treated With the Palbociclib and Letrozole Combination. (Pubmed Central) - Jun 14, 2022
Rha perhaps is an effective compound for preventing ovarian fibrosis in the future. No abstract available
- Orgalutran (ganirelix acetate) / Organon
Breast cancer, subclavian port catheter and controlled ovarian stimulation (COS): a case report highlighting a challenging combination for fertility protection (exhibition) - Jun 10, 2022 - Abstract #GSS2022GSS_419;
Despite this event, ovulation was induced with a GnRH trigger and ultrasound-guided oocyte retrieval was performed. A total of three metaphase II oocytes was vitrified.
- letrozole / Generic mfg.
Diagnosis of a spur aneurysm of the superficial cervical artery during axillary lymph node sonography (exhibition) - Jun 10, 2022 - Abstract #GSS2022GSS_418;
The diagnosis was made using high-resolution ultrasound and confirmed by angio-CT. Thus, the interventional therapy could be carried out promptly and overdiagnosis avoided.
- | letrozole / Generic mfg., anastrozole / Generic mfg., tamoxifen / Generic mfg.
Journal: Adherence to Hormonal Therapy in Breast Cancer Patients in Saudi Arabia: A Single-Center Study. (Pubmed Central) - Jun 10, 2022
Disease progression and mortality were not found to be significantly associated with hormonal therapy adherence in this study. A larger study is required to confirm the findings of our study.
- || letrozole / Generic mfg.
Retrospective data, Review, Journal: Efficacy and Safety of Letrozole in the Management of Constitutional Delay in Growth and Puberty: A Systematic Review and Meta-analysis. (Pubmed Central) - Jun 9, 2022
No increased occurrence of adverse events, spinal deformities were noted with letrozole. Letrozole is safe and effective for improving height and pubertal outcomes in CDGP, and is better than testosterone with regards to improvement in testicular volume and delaying bone-age progression.
- || Trial completion date, Trial primary completion date: Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov) - Jun 9, 2022
P1/2, N=280, Recruiting, Sponsor: Hoffmann-La Roche
Letrozole is safe and effective for improving height and pubertal outcomes in CDGP, and is better than testosterone with regards to improvement in testicular volume and delaying bone-age progression. Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023
- | letrozole / Generic mfg.
Enrollment closed, Enrollment change: Letrozole in Post-Menopausal Patients with Operable Hormone-Sensitive Breast Cancer (clinicaltrials.gov) - Jun 9, 2022
P2, N=61, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Trial completion date: Mar 2023 --> Sep 2023 | Trial primary completion date: Mar 2023 --> Sep 2023 Recruiting --> Active, not recruiting | N=300 --> 61
- | Epidaza (chidamide) / Chipscreen
New P2 trial, Metastases: Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive, HER2-negative Breast Cancer After CDK4/6 Inhibitor. (clinicaltrials.gov) - Jun 8, 2022
P2, N=73, Not yet recruiting, Sponsor: wang shusen
- | letrozole / Generic mfg.
Preclinical, Journal: Maternal aromatase inhibition via letrozole altered RFamide-related peptide-3 and gonadotropin-releasing hormone expression in pubertal female rats. (Pubmed Central) - Jun 8, 2022
Letrozole treatment at doses of 1 mg/kg BW and lower was not fetotoxic. It was concluded that 1 mg/kg BW letrozole may be suggested for prenatal PCOS induction.
- || Journal, Adverse drug reaction: Doping with aromatase inhibitors and oestrogen receptor modulators in steroid users: Analysis of a forum to identify dosages, durations and adverse drug reactions. (Pubmed Central) - Jun 8, 2022
It was concluded that 1 mg/kg BW letrozole may be suggested for prenatal PCOS induction. Patient narratives posted on forums can be a useful tool in the context of doping, to better understand practices, motivations and possibly to bring up pharmacovigilance signals.
- | letrozole / Generic mfg.
Preclinical, Journal: Effects of Fagonia indica on Letrozole-Induced Polycystic Ovarian Syndrome (PCOS) in Young Adult Female Rats. (Pubmed Central) - Jun 8, 2022
Treatment with plant also increased the levels of antioxidant enzymes. This study validates the potential of Fagonia indica for the amelioration of metabolic, as well as, hormonal disturbances that occurred in PCOS.
- | letrozole / Generic mfg.
Enrollment change, Trial completion date, Trial primary completion date: Hormone Secretion in Transgender Males (clinicaltrials.gov) - Jun 7, 2022
P4, N=40, Not yet recruiting, Sponsor: University of California, San Diego
This study validates the potential of Fagonia indica for the amelioration of metabolic, as well as, hormonal disturbances that occurred in PCOS. N=26 --> 40 | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Jun 2025 --> Jun 2028
- || letrozole / Generic mfg.
... nothing happened. Anything to share on that subject @DrLauraEsserman? #DCIS #letrozole (Twitter) - Jun 5, 2022
- ||| letrozole / Generic mfg.
Clinical: #ASCO2022 Finn PALOMA-2 final OS analysis of 1st-line palbo plus letrozole vs PLA plus let. Lots of missing data. Median OS 54 vs 51.2 mo, NS. Excluding missing patients results in somewhat better looking data, but such analyses are suspicious. (Twitter) - Jun 4, 2022
- || letrozole / Generic mfg., lenvatinib / Generic mfg.
P1/2 data, Clinical Trial,Phase I, Journal: Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer. (Pubmed Central) - Jun 4, 2022
N=26 --> 40 | Trial completion date: Dec 2025 --> Dec 2028 | Trial primary completion date: Jun 2025 --> Jun 2028 Lenvatinib plus letrozole had manageable toxicity, with target engagement and preliminary antitumor activity observed, supporting further assessment in randomized studies.
- | Ibrance (palbociclib) / Pfizer
Biomarker, Journal: Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors. (Pubmed Central) - Jun 4, 2022
The absence of progesterone receptors, presence of liver metastases, and use as second-line or beyond are associated with a reduced median PFS. One year age increase (protective factor), liver metastases (risk factor), response at initial evaluation, and best response achieved are identified as the most predictive factors of the response to this treatment regimen and of the progression risk.
- | letrozole / Generic mfg.
Journal: Modified Banxia Xiexin Decoction Ameliorates Polycystic Ovarian Syndrome With Insulin Resistance by Regulating Intestinal Microbiota. (Pubmed Central) - Jun 4, 2022
Letrozole combined with a high-fat diet was used to induce the PCOS-IR model...Genus Clostridium_sensu_stricto_1 might be the pivotal pathogenic bacteria of PCOS-IR. Modified Banxia Xiexin Decoction may ameliorate PCOS-IR by regulating intestinal microbiota imbalance and improving metabolic disorders.
- | letrozole / Generic mfg.
Journal: Interaction of letrozole and its degradation products with aromatase: chemometric assessment of kinetics and structure-based binding validation. (Pubmed Central) - Jun 4, 2022
Three main derivatives were identified after drug exposure to different degradation conditions, consisting of acid-base and oxidative environments and stressing light. Molecular docking confirmed the capability of these compounds to accommodate into the active site of the enzyme, suggesting that the sustained inhibitory activity of letrozole may be at least in part attributed to the degradation compounds.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Cyclin-dependent kinase 4/6 inhibitor treatment use in women treated for advanced breast cancer: Integrating ASCO/NCODA patient-centered standards in a community pharmacy. (Pubmed Central) - Jun 4, 2022
Molecular docking confirmed the capability of these compounds to accommodate into the active site of the enzyme, suggesting that the sustained inhibitory activity of letrozole may be at least in part attributed to the degradation compounds. A structured patient-centered pharmacy practice model integrating the ASCO/NCODA patient-centered standards and ongoing communication with patients and healthcare providers ensure timely refills, close monitoring, and allows patients to achieve high adherence and persistence rates comparable to those reported in clinical trials.
- | Herceptin (trastuzumab) / Roche
Trial completion date: HELEX: Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy (clinicaltrials.gov) - Jun 2, 2022
P2, N=128, Active, not recruiting, Sponsor: Baylor Breast Care Center
A structured patient-centered pharmacy practice model integrating the ASCO/NCODA patient-centered standards and ongoing communication with patients and healthcare providers ensure timely refills, close monitoring, and allows patients to achieve high adherence and persistence rates comparable to those reported in clinical trials. Trial completion date: Jan 2022 --> Jan 2024
- | denifanstat (TVB-2640) / Sagimet Biosci
Trial completion date, Trial primary completion date: TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer (clinicaltrials.gov) - Jun 1, 2022
P2, N=80, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Jan 2022 --> Jan 2024 Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023
- | letrozole / Generic mfg., anastrozole / Generic mfg.
Trial completion date, Trial primary completion date: Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Jun 1, 2022
P2, N=29, Recruiting, Sponsor: Mayo Clinic
Trial completion date: Jul 2022 --> Jul 2024 | Trial primary completion date: Jul 2022 --> Jul 2023 Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Jun 2023
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Journal: Development and Validation of a Novel LC-MS/MS Method for the Simultaneous Determination of Abemaciclib, Palbociclib, Ribociclib, Anastrozole, Letrozole, and Fulvestrant in Plasma Samples: A Prerequisite for Personalized Breast Cancer Treatment. (Pubmed Central) - May 30, 2022
The inter-day precision ranged from 1.6% to 14.9%, with accuracy between -14.3% and 14.6%, which is in accordance with the EMA and ICH guidelines on bioanalytical method validation. The method was successfully applied to samples from patients treated for HR+, HER2- breast cancer.
- || letrozole / Generic mfg.
بالنسبة لمتعافيات #سرطان_الثدي الهرموني اللواتي انقطعت عنهن الدورة ويتناولن العلاج الهرموني فيمارا (letrozole) أو بدائله، فمن المعتاد صرف فيتامين د وحبوب كالسيوم لهن للحفاظ على صحة العظام قد يضاف لذلك إبرة معززة للعظام (زوميتا بالوريد أو بروليا تحت الجلد) كل ٦ أشهر لتقوية العظام (Twitter) - May 27, 2022
- |||| Ibrance (palbociclib) / Pfizer
Enrollment open, Trial initiation date, Circulating tumor DNA: TRAK-ER: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer (clinicaltrials.gov) - May 26, 2022
P2, N=1100, Recruiting, Sponsor: Royal Marsden NHS Foundation Trust
The method was successfully applied to samples from patients treated for HR+, HER2- breast cancer. Not yet recruiting --> Recruiting | Initiation date: Sep 2021 --> Mar 2022
- || Mifeprex (mifepristone) / Danco Laboratories
Review, Journal: Medical methods for first trimester abortion. (Pubmed Central) - May 25, 2022
Some results are limited by the small numbers of participants on which they are based. Almost all studies were conducted in settings with good access to emergency services, which may limit the generalisability of these results.
- | letrozole / Generic mfg., exemestane / Generic mfg.
Journal: Role of Natural and Synthetic Flavonoids as Potential Aromatase Inhibitors in Breast Cancer: Structure-Activity Relationship Perspective. (Pubmed Central) - May 25, 2022
This essential feature has been utilized to modify several natural flavonoids into 5 and 7 hydroxy/methoxy flavone, 4-imidazolyl/triazolyl flavone, 5,4'- diamino flavone, 7,8- benzo-4-imidazolyl flavone, α-naphthoflavone, and 2-azole/thiazolyl isoflavone derivatives. These scaffolds have been considered in this review for meticulous study in aspects of the structure-activity relationship for aromatase inhibitory activity, and it would likely pave the way for designing a potential lead candidate in the future.
- | letrozole / Generic mfg.
Journal: Design, synthesis of novel quinazolinone-based oxobutanonitrile derivatives as antiproliferative agents targeting human breast cancer. (Pubmed Central) - May 25, 2022
The obtained results support the therapeutic importance of some of these compounds as anti-breast cancer agents in light of the simple methodology used for their synthesis. Their design offered a way for the optimization and development of apoptotic quinazolinone-based ARO and EGFR inhibitors.
- | letrozole / Generic mfg.
Retrospective data, Journal: The Effect of Spontaneous LH Surges on Pregnancy Outcomes in Patients Undergoing Letrozole-HMG IUI: A Retrospective Analysis of 6,285 Cycles. (Pubmed Central) - May 24, 2022
The presence of a spontaneous LH surge in triggered LE-HMG IUI cycles does not appear to improve pregnancy rates. Thus, we suggest that waiting for an LH surge to occur is not necessary in triggered LE-HMG IUI cycles.
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - May 24, 2022
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Thus, we suggest that waiting for an LH surge to occur is not necessary in triggered LE-HMG IUI cycles. Trial completion date: Jun 2022 --> Sep 2022
- ||||| NN1213 / Novo Nordisk
Enrollment closed: GIM10-CONSENT: CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer (clinicaltrials.gov) - May 24, 2022
P3, N=1000, Active, not recruiting, Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Trial completion date: Jun 2022 --> Sep 2022 Recruiting --> Active, not recruiting
- | zotatifin (eFT226) / eFFECTOR Therap, Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy: RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (clinicaltrials.gov) - May 24, 2022
P2, N=40, Recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2022 --> May 2023
- ||| Kisqali (ribociclib) / Novartis
P3 data, Clinical Trial,Phase III, Journal: Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial. (Pubmed Central) - May 24, 2022
Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2022 --> May 2023 These findings from the SERCE subgroup support the safety and manageable tolerability of ribociclib in a broad range of patients with HR+/HER2- ABC more representative of patients in real-world clinical practice.
- | letrozole / Generic mfg.
Journal: Aromatase Inhibition Eliminates Sexual Receptivity Without Enhancing Weight Gain in Ovariectomized Marmoset Monkeys. (Pubmed Central) - May 21, 2022
Relative estradiol levels in peripheral serum were E2 >>> VEH > LET, while those in hypothalamus ranked E2 = VEH > LET, confirming inhibition of local hypothalamic estradiol synthesis by letrozole. Our findings provide the first evidence for extra-ovarian estradiol contributing to female sexual behavior in a nonhuman primate, and prompt speculation that extra-ovarian estradiol, and in particular neuroestrogens, may similarly regulate sexual motivation in other primates, including humans.